Search results
Results from the WOW.Com Content Network
A phase I clinical trial in cancer patients was performed in 2006. [11] A phase III trial treating thyroid cancer patients started in March 2011. [12] Lenvatinib was granted orphan drug status for treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013. [13]
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
The trial investigates new approaches for men with metastatic and locally advanced prostate cancer. [1] 117 hospitals in the UK and Switzerland are involved with over 10,000 men are expected to take part in the trial. [2] The men are randomly assigned to one of a number of "arms". The primary outcome by which the arms were judged is overall ...
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
According to the American Cancer Society, "available evidence from well-designed clinical trials does not support claims that mistletoe can improve length or quality of life". [89] Modified citrus pectin – a substance chemically extracted from citrus fruits and marketed in dietary supplement form as a treatment for prostate cancer and ...
On April 14, 2009, Dendreon Corporation announced that their Phase III clinical trial of sipuleucel-T, a cancer vaccine designed to treat prostate cancer, had demonstrated an increase in survival. It received U.S. Food and Drug Administration (FDA) approval for use in the treatment of advanced prostate cancer patients on April 29, 2010. [16] [17]
Immunotherapy: mechanism of action for Durvalumab, Pembrolizumab, Ipilimumab, Atezolizumab. [20]A phase Ib clinical trial of durvalumab and tremelimumab showed some activity in non-small cell lung cancer (NSCLC) [21] Phase I data in advanced metastatic urothelial bladder (Study 1108) has led to FDA breakthrough therapy designation.
Prostate cancer staging is the process by which physicians categorize the risk of cancer having spread beyond the prostate, or equivalently, the probability of being cured with local therapies such as surgery or radiation. Once patients are placed in prognostic categories, this information can contribute to the selection of an optimal approach ...